Type 2 Diabetes: key endpoint results by drug

The key endpoints of Type 2 Diabetes trials, with each approved or late-stage drug's result from its own trial: the lead dose against placebo (or the trial's active comparator), the week, and the arm size. These are the same rows as the drug comparison, for every drug at once. To set chosen drugs side by side, with every shared endpoint, use the comparison. The drug list and pipeline are on the Type 2 Diabetes page.

HbA1c, change

HbA1c, change in Type 2 Diabetes: 57 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
Afrezza-0.7%-0.8% (Metformin & Secretagogues)—wk 12 · n 169NCT00332488 Phase 3, primary
Albenatide-0.8%-0.5%−0.41.5 mg · wk 12.14 · n 44NCT00638716 Phase 2, primary
Alogliptin-0.7%-0.1%−0.625 mg QD · wk 26 · n 126NCT00286429 Phase 3, primary
Anagliptin-0.5%a0.2%−0.7anagliptin 200 mg · wk 24NCT01529528 Phase 3, primary
Berberine ursodeoxycholate (HTD1801)-0.6%0.1%−0.71000 mg bid · wk 18 · n 26NCT03656744 Phase 2, secondary
Bexagliflozin-0.8%-0.4%−0.520 mg · wk 24 · n 1046NCT02558296 Phase 3, primary
bimagrumab-0.8%0.3%−1.110 mg/kg · wk 24 · n 36NCT03005288 Phase 2, secondary
Canagliflozin-0.4%0.4%−0.8100/300 mg · wk 26 · n 84NCT03170518 Phase 3, primary
Chiglitazar-1.1%a-0.5%−0.648mg · wk 24NCT04807348 Phase 3, primary
Cofrogliptin-1.0%a-1.1% (linagliptin 5 mg)—cofrogliptin (HSK7653) 25 mg · wk 24NCT04564872 Phase 3, primary
Dapagliflozin-0.9%-0.2%−0.710 mg AM · wk 24 · n 65NCT00528372 Phase 3, primary
Dapagliflozin/linagliptin (Dapalina)-0.8%a0.1%−0.9wk 24NCT06329674 Phase 3, primary
dulaglutide-1.3%-0.5%−0.81.5 mg · wk 24 · n 132NCT02597049 Phase 3, primary
efpeglenatide-1.6%-0.5%−1.16 mg · wk 30 · n 103NCT03353350 Phase 3, primary
efsubaglutide alfa-1.8%a-0.7%−1.1Efsubaglutide 3 mg · wk 24NCT04998032 Phase 2/3, primary
Empagliflozin-0.7%-0.2%−0.510mg · wk 24 · n 217NCT01159600 Phase 3, primary
Enavogliflozin-0.8%a-0.8% (dapagliflozin)—wk 24NCT04634500 Phase 3, primary
Ertugliflozin-1.0%0.2%−1.215 mg · wk 26 · n 151NCT01958671 Phase 3, primary
Evogliptin-0.2%a0.1%−0.3evogliptin 5mg · wk 24NCT02946541 Phase 3, primary
Gemigliptin-0.8%a0.4%−1.2wk 12NCT01968044 Phase 3, primary
glimepiride-1.1%-0.6% (Insulin Glargine)—1.5 mg · wk 52 · n 263NCT01075282 Phase 3, primary
HDG1901-2.0%a-2.0% (reference Ozempic)—wk 32NCT06739044 Phase 3, primary
IcoSema-1.6%-0.9% (Insulin Icodec)—wk 52 · n 598NCT05352815 Phase 3, primary
insulin degludec-1.4%-1.6% (Insulin Icodec)—wk 26 · n 294NCT04795531 Phase 3, primary
insulin detemir-0.5%0.0% (Lira 1.8)—wk 26 · n 160NCT00856986 Phase 3, primary
Insulin Efsitora Alfa-0.8%-0.7% (Insulin Degludec)—500 U/mL · wk 26 · n 649NCT05275400 Phase 3, primary
insulin glargine-0.6%-0.8% (Insulin Icodec)—wk 26 · n 201NCT06340854 Phase 3, primary
Insulin glargine (Basaglar)-1.3%-1.3% (Lantus)—wk 24 · n 369NCT01421459 Phase 3, primary
insulin glulisine-0.5%-0.5% (Insulin Lispro)—n 115NCT01194258 Phase 2, primary
insulin icodec-0.8%-0.6% (Insulin Glargine)—wk 26 · n 204NCT06340854 Phase 3, primary
Insulin Lispro-1.2%-1.1% (Insulin Glargine)—1.5 mg · wk 26 · n 138NCT01621178 Phase 3, primary
Insulin lispro (Lyumjev)-0.4%-0.4% (Insulin Lispro (Humalog))—wk 26 · n 334NCT03214380 Phase 3, primary
Insulin sudelidec (INS068)-1.3%a-1.4% (insulin glargine)—wk 26NCT05699408 Phase 3, primary
JW0201-0.8%a-0.0%−0.8wk 24NCT05814393 Phase 3, primary
Lanifibranor-0.7%-0.1%−0.6wk 24 · n 20NCT03459079 Phase 2, secondary
Linagliptin-0.6%0.1%−0.65 mg · wk 24 · n 618NCT00954447 Phase 3, primary
Liraglutide (Victoza)-0.6%0.4%−1.11.8 mg · wk 26 · n 66NCT01541215 Phase 3, primary
lixisenatide-0.6%0.1%−0.6wk 24 · n 172NCT01798706 Phase 3, primary
mazdutide-2.1%a-0.1%−2mazdutide 6mg · wk 24NCT05628311 Phase 3, primary
metformin0.2%0.1%+0.1wk 12 · n 46NCT02099838 Phase 4, primary
Mitiglinide-0.6%0.1%−0.7wk 16 · n 118NCT02154347 Phase 4, primary
Omarigliptin-0.3%-0.5%+0.125 mg · wk 24 · n 102NCT01814748 Phase 3, primary
orforglipron-1.4%-0.1%−1.336 mg · wk 40 · n 141NCT05971940 Phase 3, primary
ORMD-0801-0.6%-0.1%−0.5Once Daily (QHS) · wk 12 · n 59NCT03467932 Phase 2, primary
Prusogliptin-0.6%a-0.0%−0.6wk 24NCT04161430 Phase 3, primary
retatrutide-2.0%-0.1%−212 mg (2 mg) · wk 24 · n 43NCT04867785 Phase 2, primary
SAR341402-0.4%-0.3% (NovoLog/NovoRapid)—wk 26 · n 301NCT03211858 Phase 3, primary
Saxagliptin-0.7%-0.3%−0.45 mg · wk 24 · n 300NCT00757588 Phase 3, primary
Semaglutide (Ozempic)-1.6%0%−1.61.0 mg weekly · wk 30 · n 130NCT02054897 Phase 3, primary
Sitagliptin-0.6%0.2%−0.8100 mg · wk 24 · n 229NCT00087516 Phase 3, primary
Sotagliflozin (Inpefa)-0.8%-0.3%−0.5400 mg · wk 26 · n 259NCT02926950 Phase 3, primary
survodutide-1.7%-0.2%−1.42.7 mg · wk 16 · n 33NCT04153929 Phase 2, primary
Teneligliptin-0.7%-0.0%−0.720 mg · wk 24 · n 122NCT02924064 Phase 3, primary
Tirzepatide (Mounjaro)-2.1%0.0%−2.115 mg · wk 40 · n 116NCT03954834 Phase 3, primary
Trelagliptin-0.7%0.0%−0.725 mg · wk 12 · n 55NCT02512068 Phase 3, primary
Vildagliptin7.2%7.4% (SU+Metformin)—wk 24 · n 19NCT01871558 Phase 3, secondary
Visepegenatide (PB-119)-1.4%a-0.6%−0.7wk 24NCT04504370 Phase 3, primary

Drugs checked with no result here: 19 not posted, 18 trial running, 17 not reported.

Body weight, change (kg)

Body weight, change (kg) in Type 2 Diabetes: 34 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
Albenatide-2.0-1.6−0.41.5 mg · wk 12.14 · n 44NCT00638716 Phase 2, secondary
Alogliptin0.60.6±025 mg QD · wk 26 · n 124NCT00286429 Phase 3, secondary
Bexagliflozin-3.0-0.4−2.620 mg · wk 48 · n 922NCT02558296 Phase 3, secondary
bimagrumab-4.0-0.6−3.410 mg/kg · wk 24 · n 36NCT03005288 Phase 2, secondary
Canagliflozin-2.9-0.8−2.1300 mg daily · wk 12 · n 62NCT00642278 Phase 2, secondary
Dapagliflozin-3.2-2.2−110 mg AM · wk 24 · n 69NCT00528372 Phase 3, secondary
dulaglutide-0.80.4−1.21.5 mg · wk 28 · n 133NCT04591626 Phase 3, secondary
efpeglenatide-3.2-1.4−1.86 mg · wk 30 · n 103NCT03353350 Phase 3, secondary
Empagliflozin-2.1-0.4−1.710mg · wk 24 · n 217NCT01159600 Phase 3, secondary
Ertugliflozin-2.3-0.4−1.915 mg · wk 18 · n 2746NCT01986881 Phase 3, secondary
glimepiride-2.40.1 (Glim)—1.8 mg · wk 16 · n 224NCT00614120 Phase 3, secondary
IcoSema-3.72.0 (Insulin Icodec)—wk 52 · n 606NCT05352815 Phase 3, secondary
insulin degludec2.32.8 (Insulin Icodec)—wk 26 · n 294NCT04795531 Phase 3, secondary
insulin detemir-0.2-0.9 (Lira 1.8)—wk 26 · n 162NCT00856986 Phase 3, secondary
Insulin Efsitora Alfa3.22.7 (Insulin Degludec)—wk 26 · n 465NCT05362058 Phase 3, secondary
insulin glargine0.62.0 (Insulin Icodec)—wk 26 · n 202NCT06340854 Phase 3, secondary
Insulin glargine (Basaglar)1.92.2 (Lantus)—wk 24 · n 370NCT01421459 Phase 3, secondary
insulin glulisine0.50.2 (Insulin Glargine+Metformin+Glimepiride)—wk 24 · n 48NCT00360698 Phase 4, secondary
insulin icodec2.00.6 (Insulin Glargine)—wk 26 · n 204NCT06340854 Phase 3, secondary
Insulin Lispro-2.81.1 (Insulin Glargine)—1.5 mg · wk 26 · n 140NCT01621178 Phase 3, secondary
Linagliptin1.4-0.0+1.55 mg · wk 26 · n 49NCT03429543 Phase 3, secondary
Liraglutide (Victoza)-2.5-0.9−1.61.8 mg · wk 26 · n 60NCT01541215 Phase 3, secondary
lixisenatide-0.61.0 (Insulin Glulisine)—wk 26 · n 295NCT01768559 Phase 3, primary
metformin-0.4-1.1 (Met)—5 mg once daily + metformin once daily · wk 14 · n 287NCT01438814 Phase 4, secondary
Omarigliptin-0.41.5 (Glimepiride)—wk 54 · n 375NCT01682759 Phase 3, secondary
orforglipron-7.3-1.3−636 mg · wk 40 · n 141NCT05971940 Phase 3, secondary
retatrutide-12.8-1.9−1112 mg (2 mg) · wk 24 · n 43NCT04867785 Phase 2, secondary
Saxagliptin-1.9-0.4−1.5wk 24 · n 158NCT01646320 Phase 3, secondary
Semaglutide (Ozempic)-4.9-0.6−4.31.0 mg · wk 104 · n 822NCT01720446 Phase 3, secondary
Sitagliptin-0.5-1.4 (Oral Semaglutide)—100 mg · wk 26 · n 335NCT04017832 Phase 3, secondary
Sotagliflozin (Inpefa)-2.6-0.7−1.9400 mg · wk 26 · n 259NCT02926950 Phase 3, secondary
survodutide-6.9-1.3−5.62.7 mg · wk 16 · n 33NCT04153929 Phase 2, secondary
Tirzepatide (Mounjaro)-9.5-0.7−8.815 mg · wk 40 · n 116NCT03954834 Phase 3, secondary
Vildagliptin-0.31.4 (SU+Metformin)—wk 24 · n 21NCT01871558 Phase 3, secondary

Drugs checked with no result here: 38 not posted, 19 trial running, 20 not reported.

HbA1c below 7%

HbA1c below 7% in Type 2 Diabetes: 26 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
Alogliptin63.3%30%+33.3wk 16 · n 90NCT01289119 Phase 3, secondary
Canagliflozin42.8%43% (Metformin XR)—300 mg · wk 26 · n 215NCT01809327 Phase 3, secondary
Dapagliflozin50.8%31.6%+19.210 mg AM · wk 24 · n 65NCT00528372 Phase 3, secondary
dulaglutide75.9%33.8%+42.11.5 mg · wk 28 · n 133NCT04591626 Phase 3, secondary
Empagliflozin34.6%24.5%+10.110 mg, 25 mg · wk 26 · n 52NCT03429543 Phase 3, secondary
Ertugliflozin28.2%15.5%+12.715 mg · wk 18 · n 2520NCT01986881 Phase 3, secondary
glimepiride62.8%72.3% (Liraglutide)—wk 26 · n 269NCT01296412 Phase 3, secondary
insulin degludec75.3%35.6% (Liraglutide or Exenatide)—wk 26 · n 292NCT01676116 Phase 3, secondary
insulin glargine48.4%45.9% (Liraglutide)—wk 24 · n 467NCT01117350 Phase 4, primary
Insulin glargine (Basaglar)43.7%44.9% (Lantus®)—wk 24 · n 334NCT03338010 Phase 3, secondary
insulin glulisine22.4%8.8% (Insulin Glargine+Metformin+Glimepiride)—wk 24 · n 49NCT00360698 Phase 4, primary
Insulin Lispro37.5%34.6% (Insulin Glargine)—1.5 mg · wk 26 · n 152NCT01621178 Phase 3, secondary
Linagliptin26.9%24.5%+2.45 mg · wk 26 · n 52NCT03429543 Phase 3, secondary
Liraglutide (Victoza)63.7%36.5%+27.21.8 mg · wk 26 · n 66NCT01541215 Phase 3, secondary
lixisenatide53%38.8%+14.2wk 24 · n 185NCT01169779 Phase 3, secondary
metformin48.4%45.9% (Liraglutide)—wk 24 · n 467NCT01117350 Phase 4, primary
Omarigliptin33.5%34%−0.525 mg · wk 24 · n 102NCT01814748 Phase 3, secondary
orforglipron79.0%37.1%+41.936 mg · wk 40 · n 119NCT05971940 Phase 3, secondary
retatrutide86%18%+6812 mg (2 mg) · wk 24 · n 43NCT04867785 Phase 2, secondary
rexlemestrocel-L33%a0%+33—NCT01576328 Phase 1/2, primary
SAR34140216.6%14.5% (NovoLog/NovoRapid)—wk 26 · n 301NCT03211858 Phase 3, secondary
Saxagliptin44.4%16.6%+27.810 mg · wk 24 · n 180NCT00121667 Phase 3, secondary
Semaglutide (Ozempic)72.3%24.8%+47.51.0 mg weekly · wk 30 · n 130NCT02054897 Phase 3, secondary
Sitagliptin49.5%36.8%+12.7wk 20 · n 95NCT01485614 Phase 3, secondary
Sotagliflozin (Inpefa)29.7%15.8%+13.9400 mg · wk 26 · n 259NCT02926950 Phase 3, secondary
Tirzepatide (Mounjaro)87.9%19.6%+68.315 mg · wk 40 · n 116NCT03954834 Phase 3, secondary

Drugs checked with no result here: 44 not posted, 20 trial running, 21 not reported.

Fasting plasma glucose, change

Fasting plasma glucose, change in Type 2 Diabetes: 30 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
Albenatide-0.8-0.6−0.21.5 mg · wk 12.14 · n 42NCT00638716 Phase 2, secondary
Alogliptin-0.70.3−125 mg QD · wk 26 · n 128NCT00286429 Phase 3, secondary
Bexagliflozin-2.5-1.2−1.320 mg · wk 24 · n 142NCT03259789 Phase 3, secondary
Canagliflozin-0.60.2−0.7300 mg · wk 338 · n 1377NCT01032629 Phase 3, secondary
Dapagliflozin-1.30.2−1.5wk 24 · n 222NCT00984867 Phase 3, secondary
dulaglutide-2.4-2.6 (Insulin Glargine)—1.5 mg · wk 26 · n 253NCT01648582 Phase 3, secondary
efpeglenatide6.58.6−26 mg · wk 30 · n 103NCT03353350 Phase 3, secondary
Empagliflozin-1.80.3−2.125 mg + 5 mg · wk 24 · n 109NCT01734785 Phase 3, secondary
Ertugliflozin-1.9-0.9−115 mg · wk 18 · n 2747NCT01986881 Phase 3, secondary
glimepiride-0.90.3 (Glimepiride)—25 mg QD · wk 12 · n 104NCT01318083 Phase 2/3, secondary
IcoSema-1.9-1.6 (Insulin Icodec)—wk 52 · n 552NCT05352815 Phase 3, secondary
insulin degludec-3.0-3.0 (Insulin Icodec)—wk 26 · n 290NCT04795531 Phase 3, secondary
insulin detemir-2.1-0.4 (Lira 1.8)—wk 26 · n 160NCT00856986 Phase 3, secondary
insulin glargine-3.6-2.1 (Liraglutide)—wk 24 · n 468NCT01117350 Phase 4, secondary
insulin icodec-3.0-3.0 (Insulin Degludec)—wk 26 · n 284NCT04795531 Phase 3, secondary
Insulin Lispro-2.0-1.5 (Insulin Lispro + Insulin Glargine)—wk 26 · n 345NCT02229227 Phase 3, secondary
Linagliptin-0.40.3−0.65 mg · wk 24 · n 614NCT00954447 Phase 3, secondary
Liraglutide (Victoza)-1.10.8−1.91.8 mg · wk 26 · n 66NCT01541215 Phase 3, secondary
lixisenatide-0.30.0−0.3wk 24 · n 171NCT01798706 Phase 3, secondary
metformin0.30.0+0.2wk 12 · n 46NCT02099838 Phase 4, secondary
Omarigliptin-0.3-0.1−0.225 mg · wk 24 · n 102NCT01814748 Phase 3, secondary
orforglipron-2.0-1.1−0.93/6/12/21 mg QD · wk 12 · n 7NCT04426474 Phase 1, secondary
SAR341402-0.5-0.2 (NovoLog/NovoRapid)—wk 26 · n 301NCT03211858 Phase 3, secondary
Saxagliptin-0.6-0.3−0.25 mg · wk 24 · n 300NCT00757588 Phase 3, secondary
Semaglutide (Ozempic)-2.1-0.9−1.21.0 mg · wk 104 · n 822NCT01720446 Phase 3, secondary
Sitagliptin-0.70.3−0.9100 mg · wk 24 · n 234NCT00087516 Phase 3, secondary
Sotagliflozin (Inpefa)-1.3-0.6−0.8400 mg · wk 26 · n 259NCT02926950 Phase 3, secondary
Teneligliptin-0.80.2−0.920 mg · wk 24 · n 122NCT02924064 Phase 3, secondary
Trelagliptin-0.9-0.0−0.925 mg · wk 12 · n 55NCT02512068 Phase 3, secondary
Vildagliptin-1.2-0.0−1.2wk 12 · n 78NCT02002221 Phase 4, secondary

Drugs checked with no result here: 40 not posted, 19 trial running, 22 not reported.

3-point MACE (% with event)

3-point MACE (% with event) in Type 2 Diabetes: 8 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
Alogliptin11.3%11.8%−0.5n 2701NCT00968708 Phase 3, primary
dulaglutide12%13.4%−1.4n 4949NCT01394952 Phase 3, primary
Empagliflozin10.4%12.1%−1.710 mg · n 2345NCT01131676 Phase 3, primary
Linagliptin20.7%21.2% (Glimepiride)—wk 432 · n 3023NCT01243424 Phase 3, primary
Liraglutide (Victoza)13%14.9%−1.9wk 260 · n 4668NCT01179048 Phase 3, primary
Saxagliptin7.4%7.4%±0n 8280NCT01107886 Phase 4, primary
Semaglutide (Ozempic)6.6%8.9%−2.3n 1648NCT01720446 Phase 3, primary
Tirzepatide (Mounjaro)12.2%13.1% (Dulaglutide)—MTD · wk 259 · n 6586NCT04255433 Phase 3, primary

Drugs checked with no result here: 56 not posted, 27 not reported, 20 trial running.

  1. a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. Rows are in drug-name order, not ranked. Difference is the lead arm minus placebo, in the endpoint's unit. 111 approved or late-stage drugs with a featured trial in Type 2 Diabetes were checked; results come from ClinicalTrials.gov posted results unless marked. Updated 2026-11-20. How results are chosen: methodology.